Predictors of treatment allocation guesses in a randomized controlled trial testing double-blind injectable hydromorphone and diacetylmorphine for severe opioid use disorder

References

• Akaike H. 1987. Factor analysis and AIC. Psychometrika. 52:317–332.
   Web of Science ®Google Scholar
• Boutron I, Estellat C, Ravaud P. 2005. A review of blinding in randomized controlled trials found results inconsistent and questionable. J Clin Epidemiol. 58:1220–1226.
   PubMed Web of Science ®Google Scholar
• Brown LA, Wiley JF, Wolitzky-Taylor K, Roy-Byrne P, Sherbourne C, Stein MB, Sullivan G, Rose RD, Bystritsky A, Craske MG. 2014. Changes in self-efficacy and outcome expectancy as predictors of anxiety outcomes from the CALM study. Depress Anxiety. 31:678–689.
   PubMed Web of Science ®Google Scholar
• Buchanan TS, Sanderson Cox L, Thomas JL, Nollen NL, Berg CJ, Mayo MS, Ahluwalia JS. 2013. Perceived treatment assignment and smoking cessation in a clinical trial of bupropion versus placebo. Nicotine Tob Res. 15:567–571.
   PubMed Web of Science ®Google Scholar
• Bull SB, Lewinger JP, Lee SS. 2007. Confidence intervals for multinomial logistic regression in sparse data. Stat Med. 26:903–918.
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. 2014. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 71:821–826.
   PubMed Web of Science ®Google Scholar
• Colagiuri B, Boakes RA. 2010. Perceived treatment, feedback, and placebo effects in double-blind RCTs: an experimental analysis. Psychopharmacology (Berl). 208:433–441.
   PubMed Web of Science ®Google Scholar
• Colagiuri B, Morley K, Boakes R, Haber P. 2009. Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence. Psychother Psychosom. 78:167–171.
   PubMed Web of Science ®Google Scholar
• Colagiuri B. 2010. Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity. Clin Trials. 7:246–255.
   PubMed Web of Science ®Google Scholar
• Correa JB, Heckman BW, Marquinez NS, Drobes DJ, Unrod M, Roetzheim RG, Brandon TH. 2014. Perceived medication assignment during a placebo-controlled laboratory study of varenicline: temporal associations of treatment expectancies with smoking-related outcomes. Psychopharmacology (Berl). 231:2559–2566.
   PubMed Web of Science ®Google Scholar
• Crow R, Gage H, Hampson S, Hart J, Kimber A, Thomas H. 1999. The role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review. Health Technol Assess. 3:1–110.
   PubMedGoogle Scholar
• Dar R, Barrett SP. 2014. The effects of beliefs regarding drug assignment in experimental and field studies of nicotine delivery devices: a review. J Psychopharmacol (Oxford). 28:1071–1079.
   PubMed Web of Science ®Google Scholar
• Demaret I, Quertemont E, Litran G, Magoga C, Deblire C, Dubois N, De Roubaix J, Charlier C, Lemaitre A, Ansseau M. 2015. Efficacy of heroin-assisted treatment in Belgium: a randomised controlled trial. Eur Addict Res. 21:179–187.
   PubMed Web of Science ®Google Scholar
• Drewes AM, Jensen RD, Nielsen LM, Droney J, Christrup LL, Arendt-Nielsen L, Riley J, Dahan A. 2013. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol. 75:60–78.
   PubMed Web of Science ®Google Scholar
• Ferri M, Davoli M, Perucci CA. 2011. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 12:1–55.
   Google Scholar
• Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. 2007. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 191:55–62.
   PubMed Web of Science ®Google Scholar
• Kolahi J, Bang H, Park J. 2009. Towards a proposal for assessment of blinding success in clinical trials: up-to-date review. Commun Dent Oral Epidemiol. 37:477–484.
   PubMed Web of Science ®Google Scholar
• March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. 2006. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat. 31:203–211.
   PubMed Web of Science ®Google Scholar
• Marchand KI, Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Schechter MT. 2011. Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency. BMC Health Serv Res. 11:174.
   PubMed Web of Science ®Google Scholar
• Marsden J, Gossop M, Stewart D, Best D, Farrell M, Lehmann P, Edwards C, Strang J. 1998. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction (Abingdon, England). 93:1857–1867.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. 2009. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2:1–34.
   Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. 2014. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2:1–88.
   Google Scholar
• Mead N, Bower P. 2000. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med. 51:1087–1110.
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT. 2009. Diacetylmorphine versus methadone for the treatment of opioid addiction. NEJM. 361:777–786.
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, Harrison S, Janmohamed A, Anis AH, Krausz M, et al. 2016. Hydromorphone compared with diacetylmorphine for long-term opioid dependence. A randomized clinical trial. JAMA Psychiatry. 73:1–9.
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Marchand K, Guh D, MacDonald S, Lock K, Brissette S, Anis AH, Krausz M, Schechter MT. 2015b. History of treatment access and drug use among participants in a trial testing injectable opioids under supervision for long-term heroin injectors. J Addict Med Ther. 3:1015.
   Google Scholar
• Oviedo-Joekes E, Marchand K, Lock K, MacDonald S, Guh D, Schechter MT. 2015a. The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency. Subst Abuse Treat Prev Policy. 10:3.
   PubMed Web of Science ®Google Scholar
• Perneger TV, Giner F, del Rio M, Mino A. 1998. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ. 317:13–18.
   PubMed Web of Science ®Google Scholar
• Preston KL, Bigelow GE. 2000. Effects of agonist–antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. J Pharmacol Exp Ther. 295:114–124.
   PubMed Web of Science ®Google Scholar
• Schensul SL, Schensul Jean J, LeCompte, Margaret D. 1999. Essential ethnographic methods: observations, interviews, and questionnaires. United Kingdom: Rowman Altamira.
   Google Scholar
• Schnoll RA, Epstein L, Audrain J, Niaura R, Hawk L, Shields PG, Lerman C, Wileyto EP. 2008. Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation. J Subst Abuse Treat. 34:234–241.
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D, Fergusson D. 2010. CONSORT 2010 changes and testing blindness in RCTs. Lancet. 375:1144–1146.
   PubMed Web of Science ®Google Scholar
• Schulz KF, Grimes DA. 2002. Blinding in randomised trials: hiding who got what. Lancet. 359:696–700.
   PubMed Web of Science ®Google Scholar
• Starks H, Trinidad SB. 2007. Choose your method: a comparison of phenomenology, discourse analysis, and grounded theory. Qual Health Res. 17:1372–1380.
   PubMed Web of Science ®Google Scholar
• Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, Williams H, Zador D, Evers R, Groshkova T, et al. 2010. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet. 375:1885–1895.
   PubMed Web of Science ®Google Scholar
• Thomas JL, Guo H, Lynam IM, Powell JN, Okuyemi KS, Bronars CA, Ahluwalia JS. 2008. The impact of perceived treatment assignment on smoking cessation outcomes among African-American smokers. J Gen Intern Med. 23:1361–1366.
   PubMed Web of Science ®Google Scholar
• Trujols J, Garijo I, Sinol N, del Pozo J, Portella MJ, Perez de los Cobos J. 2012. Patient satisfaction with methadone maintenance treatment: the relevance of participation in treatment and social functioning. Drug Alcohol Depend. 123:41–47.
   PubMed Web of Science ®Google Scholar
• van den Brink W, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, van Ree JM. 2003. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 327:310–316.
   PubMed Web of Science ®Google Scholar
• Walker DJ, Zacny JP, Galva KE, Lichtor JL. 2001. Subjective, psychomotor, and physiological effects of cumulative doses of mixed-action opioids in healthy volunteers. Psychopharmacology (Berl). 155:362–371.
   PubMed Web of Science ®Google Scholar
• Walker DJ, Zacny JP. 1999. Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. J Pharmacol Exp Ther. 289:1454–1464.
   PubMed Web of Science ®Google Scholar
• Wright S, Duncombe P, Altman DG. 2012. Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach. Trials. 13:189–200.
   PubMed Web of Science ®Google Scholar